Inspire Medical Systems (INSP) delivered a quarter that looks better in its business trajectory than in its headline numbers. Adjusted EPS of $0.14 cleared the $0.10 consensus estimate but fell well short of the $0.20 Earnings Whisper number, a 30.0% miss against the expectation that mattered most to engaged investors. Revenue of $206.7 million beat the $204.3 million consensus by 1.2%. Even so, the year-over-year comparisons remain harsh. Earnings fell 63.2% and revenue declined 7.9% as coding and reimbursement disruption continued to weigh on U.S. procedures. The central tension is that the numbers still reflect a business in contraction, while the call made the strongest case yet that the worst of the disruption is in the rear-view mirror.

The quality of the quarter deserves scrutiny on both sides. On a GAAP basis, Inspire swung to a net loss of $24.4 million, or $(0.84) per share, from a $0.34 profit a year earlier. That loss was driven by $24.1 million of Project Horizon restructuring charges, a $7.0 million settlement of a pixel-tracking class action, and higher legal fees tied to the DOJ civil investigative demand and the Nyxoah patent litigation. Stripping those out, the underlying picture is more disciplined than the GAAP line suggests:

• Adjusted operating expenses fell to $176.0 million from $181.8 million.
• Adjusted operating income of $1.9 million beat management's roughly breakeven guidance.
• Gross margin edged up 20 basis points to 86.0% on a richer Inspire V mix.

However, adjusted EBITDA margin slipped 130 basis points to 18.3%, and inventory climbed to $179.0 million from $145.3 million at year-end. Cash generation remained solid, with $46.4 million in quarterly operating cash flow and $453.1 million in cash and investments with no debt.

What changed most was the trajectory beneath the headline:

• **Sequential growth.** Revenue rose about 3% from the second quarter and landed at the better end of the guided 8%-10% decline.
• **Shrinking headwind.** The estimated full-year coding headwind narrowed again, to roughly $120 million from $120-$130 million last quarter and $120-$150 million in the first quarter. The quarterly hit eased from about $40 million to about $30 million.
• **Firmer tone.** Management's language moved from "temporary disruption" to "much of the disruption is behind us." CEO Tim Herbert pointed to greater comfort among implanting physicians with the current coding dynamic.
• **First 2027 outlook.** Most importantly, management offered its first 2027 framework, calling for low single-digit worldwide revenue growth. That is a meaningful step from declining to guide at all on the second-quarter call.

The catalyst list is longer than it has been in some time:

• The AMA approved a Category I CPT code for single-lead hypoglossal nerve stimulation, including Inspire V, effective January 2028. This reverses the April rejection.
• CMS proposed 2027 outpatient facility rate increases of 12% for hospitals and 15% for ambulatory surgery centers.
• Project Horizon is redirecting roughly $30 million toward about 40 net field additions, a new cardiology referral channel, and growing battery-replacement revenue.
• Inspire 6 is targeted for FDA submission in 2027.

Bears still have legitimate ammunition, however:

• International revenue fell about 9% on German destocking, and fourth-quarter international sales are guided only flat.
• U.S. territory count declined for a fifth straight quarter.
• GLP-1 drugs remain a cited headwind.
• The RUC valuation process could lower surgeon professional fees given Inspire V's shorter procedure time.

Guidance reflects the same push and pull. The 2026 revenue range was narrowed to $850-$860 million around an unchanged midpoint, with the top end cut from $875 million. The adjusted operating margin range moved to 4.5%-5.5%, trimming the high end from 6%. The adjusted EPS midpoint rose to $1.30 from $1.25. With only $0.38 earned through nine months, that target leaves a heavy fourth-quarter burden. The call analysis also noted that the guidance midpoint implies year-over-year deceleration in the fourth quarter versus the third. The full-year bar remains far below the original $950 million to $1 billion outlook.

Investor sentiment remains firmly negative but improved modestly, rising from -0.60 to -0.55. That is a slight thaw rather than a reversal. The stock has behaved better than sentiment implies. Shares closed at $68.10 ahead of the report, up 6.1% since the open after the August release and about 15.9% above the 200-day moving average of $58.75. The path was volatile. Shares rallied from an inter-earnings low of $55.44 in mid-August to a high of $78.80 on September 18, the month of the CPT approval, then gave back a good portion of that move, entering the report 13.6% below the high. Price, sequential-growth, and AVWAP trend readings are positive, consistent with a stock that has already been rewarded for stabilization.

The bottom line is that Inspire's third quarter was a transition report rather than a clean win. The miss against the whisper, the GAAP loss, and the still-shrinking top line keep the burden of proof on management. Meanwhile, the narrowing reimbursement headwind, the CPT code, and an explicit 2027 return-to-growth outlook give the recovery thesis more substance than it had three months ago. With shares well off their lows but below the September peak, investors now need fourth-quarter execution and the final CMS rule to show that stabilization can become actual growth.